Breaking Finance News

CTI BioPharma Corp (NDAQ:CTIC) target price upped to $7.50, issued a ratings update earlier today by Jefferies & Co

Having a price of $3.29, CTI BioPharma Corp (NDAQ:CTIC) traded 2.12% higher on the day. With the last stock price down -12.61% from the two hundred day average, compared with the S&P 500 Index which has increased 0.04% over the date range. CTI BioPharma Corp has recorded a 50-day average of $3.35 and a two hundred day average of $3.79. Trading volume was up over the average, with 752,794 shares of CTIC changing hands over the typical 106,805

In a report announced on 9/12/2017 Jefferies & Co raised the target price of CTI BioPharma Corp (NDAQ:CTIC) to $7.50 stating a potential upside of 1.28%.

See Chart Below

CTI BioPharma Corp (NDAQ:CTIC)

With a total market value of $0, CTI BioPharma Corp has with a one year low of $2.70 and a 52 week high of $6.48 .

General Information About CTI BioPharma Corp (NDAQ:CTIC)

CTI BioPharma Corp. (CTI) is a biopharmaceutical company focused on the acquisition, development and commercialization of targeted therapies covering a spectrum of blood-related cancers to patients and healthcare providers. The Company is primarily focused on commercializing PIXUVRI in select countries in the European Union, for multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL). It is also engaged in evaluating pacritinib for the treatment of adult patients with myelofibrosis. Its earlier stage product candidate, tosedostat, is an oral, once-daily aminopeptidase inhibitor that has demonstrated responses in patients with acute myeloid leukemia (AML). It also evaluates its pipeline candidate paclitaxel poliglumex (Opaxio), which targets solid tumors. It is evaluating Opaxio through cooperative group sponsored trials and investigator-sponsored trials (ISTs), such as the ongoing maintenance therapy trial in patients with ovarian cancer.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.